Fujita Sachio, Matsuno Ryosuke, Kawabata Naoko, Sugishita Yumiko, Kaneko Ryota, Koganesawa Masaya, Akiyama Kosuke, Toyama Daisuke, Yamamoto Shohei
Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
SAGE Open Med Case Rep. 2021 May 13;9:2050313X211015511. doi: 10.1177/2050313X211015511. eCollection 2021.
Limited salvage chemotherapies are available for relapsed/refractory acute myeloid leukemia. Herein, we described successful reinduction chemotherapy, involving a combination of clofarabine, cyclophosphamide, and etoposide, in a 12-year-old male with relapsed acute myeloid leukemia prior to allogeneic bone marrow transplantation from his father. Although treatment with a combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin, and gemtuzumab ozogamicin had no positive effects, the aforementioned clofarabine-based chemotherapy induced complete remission and allowed the transplantation to go ahead. The abovementioned regimen may be useful for induction chemotherapy prior to hematopoietic stem cell transplantation for refractory/relapsed acute myeloid leukemia.
对于复发/难治性急性髓系白血病,可用的挽救性化疗方法有限。在此,我们描述了一名12岁男性在接受来自其父亲的异基因骨髓移植前复发急性髓系白血病时,成功进行再诱导化疗的案例,该化疗方案包括氯法拉滨、环磷酰胺和依托泊苷联合使用。尽管使用氟达拉滨、阿糖胞苷、粒细胞集落刺激因子、伊达比星和吉妥珠单抗奥佐米星联合治疗没有产生积极效果,但上述基于氯法拉滨的化疗诱导了完全缓解,并使移植得以进行。上述方案可能对难治性/复发性急性髓系白血病造血干细胞移植前的诱导化疗有用。